mocka
The scientific day of the PIRAMID program took place on Friday, September 25, 2020 with the guest speaker Dr Marc BAADEN, director of the Laboratory of Theoretical Biochemistry (UPR 9080), Institut de Biologie Physico-Chimique (CNRS), Paris.
PIRAMID PhD students, including Jimmy Smadja from the Mocka Lab, and post-doctoral fellows also participated in this Scientific Day through various scientific presentations of their research work.
SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that the first patient has been dosed in Part B of the ongoing Phase 1/1b study of IL-15 superagonist, SO-C101, for the treatment of patients with advanced/metastatic solid tumors. Part B will examine SO-C101 in combination with PD-1 inhibitor pembrolizumab. The trial is conducted in partnership with Cytune Pharma.
July 14, 2020
Source: Press Release
SOTIO, a clinical stage immuno-oncology company and Cytune Pharma, both owned by PPF Group, announced that they will present new preclinical data on SO-C101, an IL-15 superagonist currently being studied in a Phase 1 trial for the treatment of advanced solid tumors, in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II being held from June 22-24, 2020.
June 15, 2020
Source: Press Release
SOTIO and Cytune Pharma from the PPF Group, today presented new preclinical data highlighting the therapeutic potential of SO-C101, an IL-15 superagonist, as a monotherapy and in combination with PD-1 inhibitors in multiple tumor models. The data were presented in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II.
June 22, 2020
Source: Press Release
Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacitidine. By: Brammer E., Boles A.E., Mansour A., Freud A.G., Mathé-Allainmat M., Quéméner A., Mortier E., Porcu P. and Mishra A. Blood (2019) 134 (Splt. 1): 3776. DOI: https://doi.org/10.1182/blood-2019-131174
BTN2A, a New Immune-Checkpoint Targeting Vg9Vd2 T Cell Cytotoxicity. By: Cano C.E. Pasero C., De Gassart A., Hoet R., Scotet E., Mortier E., Quéméner A., Rafia C., Briantais A., Le Floch A.-C., and Olive D. Blood (2019) 134 (Splt. 1): 1044. DOI: https://doi.org/10.1182/blood-2019-128658
New publication from the Mocka Lab! IL-15Rα membrane anchorage in either cis or trans is required for stabilization of IL-15 and optimal signaling by Quéméner et al. published in the Journal of Cell Science
see « Publications » section
New review from the Mocka Lab! «NK Cell Hyporesponsiveness: More Is Not Always Better» by Marie Frutoso and Erwan MORTIER published in International Journal of Molecular Science.
see « Publications » section
SOTIO and Cytune Pharma, members of the PPF Group, announce today the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15. The phase I/Ib study (SC103) will evaluate the safety and preliminary efficacy of SO-C101 in patients with selected advanced/metastatic solid tumors.
July 11, 2019
Source: Press Release
The scientific day of the PIRAMID program was held on Monday, July 15, 2019 with the guest speaker Dr Stéphane Betzi from the Marseille Cancer Center.
PIRAMID PhD students, including Jimmy Smadja from the Mocka Lab, also participated in this Scientific Day through various scientific presentations of their research work.
New publication from the Mocka Lab! «Mechanistic and Structural Insights on the IL-15 System through Molecular Dynamics Simulations» by Rui Sousa et al., published in Molecules. Article in collaboration with Prof. Le Questel and Dr. Laurent from the ModES team, of the CEISAM laboratory, CNRS UMR6230, Université of Nantes).
see « Publications » section
SOTIO, a biotechnology company belonging to the PPF Group, announces today that it received a positive decision further to the EU Voluntary Harmonisation Procedure (VHP) for the review of clinical trial application for the first-in-human clinical trial, study SC103, with its lead oncology asset SO-C101, a human fusion protein of IL-15 and the high-affinity binding domain of IL-15Rα. Study SC103 is a phase I/Ib study to evaluate the safety and preliminary efficacy of SO-C101 in patients with selected advanced/metastatic solid tumors. SOTIO expects to initiate the trial as soon as the concerned national (France and Spain) regulatory agencies and ethics committee approvals are granted. Enrolment of the first patient is planned in May 2019.
February 4, 2019
Source: Press Release, Prague